EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Fusion Antibodies's enterprise value is £3.18 Mil.
Fusion Antibodies's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was £1.58 Mil. Therefore, Fusion Antibodies's EV-to-Revenue for today is 2.02.
The historical rank and industry rank for Fusion Antibodies's EV-to-Revenue or its related term are showing as below:
LSE:FAB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.07 Med: 4.77 Max: 24.43
Current: 2.01
During the past 9 years, the highest EV-to-Revenue of Fusion Antibodies was 24.43. The lowest was 0.07. And the median was 4.77.
LSE:FAB's EV-to-Revenue is ranked better than 80.17% of 1039
companies
in the Biotechnology industry
Industry Median: 8.18
vs LSE:FAB: 2.01
The historical data trend for Fusion Antibodies's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fusion Antibodies's EV-to-Revenue
For the Biotechnology subindustry, Fusion Antibodies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's EV-to-Revenue falls into.
Fusion Antibodies's current Enterprise Value is £3.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was £1.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies's share price for today is £0.038.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Sep. 2023 was £0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Fusion Antibodies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:FAB has been successfully added to your 